title: Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
abstract: In this study we compared Pittsburgh compound-B (PIB) positron emission tomography (PET) amyloid imaging, fluorodeoxyglucose PET for metabolism, and magnetic resonance imaging (MRI) for structure to predict conversion from amnestic mild cognitive impairment (MCI) to Alzheimer's dementia using data from the Alzheimer's Disease Neuroimaging Initiative cohort. Numeric neuroimaging variables generated by the Alzheimer's Disease Neuroimaging Initiative-funded laboratories for each neuroimaging modality along with apolipoprotein-E genotype (n = 29) were analyzed. Performance of these biomarkers for predicting conversion from MCI to Alzheimer's dementia at 2 years was evaluated in 50 late amnestic MCI subjects, 20 of whom converted. Multivariate modeling found that among individual modalities, MRI had the highest predictive accuracy (67%) which increased by 9% to 76% when combined with PIB-PET, producing the highest accuracy among any biomarker combination. Individually, PIB-PET generated the best sensitivity, and fluorodeoxyglucose PET had the lowest. Among individual brain regions, the temporal cortex was found to be most predictive for MRI and PIB-PET.
authors: Eli Lilly and Company, Indianapolis, IN, USA; Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: trzepacz_paula_t@lilly.com.
authors: Paula T
authors: PT
authors: Trzepacz
authors: Peng
authors: P
authors: Yu
authors: Jia
authors: J
authors: Sun
authors: Kory
authors: K
authors: Schuh
authors: Michael
authors: M
authors: Case
authors: Michael M
authors: MM
authors: Witte
authors: Helen
authors: H
authors: Hochstetler
authors: Ann
authors: A
authors: Hake
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000682:Amyloid / Q000378:metabolism; D000814:Aniline Compounds; D001057:Apolipoproteins E / Q000235:genetics; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology*; D060825:Cognitive Dysfunction / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005544:Forecasting; D005838:Genotype; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D059906:Neuroimaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013702:Temporal Lobe; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000682:Amyloid; D000814:Aniline Compounds; D001057:Apolipoproteins E; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18
keywords: ADNI; Alzheimer's disease; Amyloid imaging; ApoE; Biomarkers; Conversion; Dementia; FDG-PET; MRI; Mild cognitive impairment; Neuroimaging; PIB-PET